Monitor for further development milestones, such as facility leasing or regulatory approvals. The stock may see speculative interest, but given the $4M market cap and early stage, volatility is likely. No concrete financial data to support immediate re-rating.
Price Chart
Executive Summary
Callan JMB announced a strategic partnership with Alabama State University to support a pharmaceutical manufacturing ecosystem, with potential revenue of $105M annually at full scale. However, the initiative is early-stage, subject to execution risk, and the company has a market cap of only $4M, making the $414M five-year opportunity highly speculative.
Key Facts
- Partnership with Alabama State University to develop an integrated pharmaceutical manufacturing ecosystem.
- Callan JMB would receive 21% of gross revenue from qualifying pharmaceutical manufacturing operations.
- Management estimates potential annual gross revenues of $500M, implying ~$105M annual revenue for Callan JMB.
- Initiative is early-stage and subject to successful execution.
- Market cap is $4M, making the potential revenue highly speculative relative to current size.
Financial Impact
Potential $105M annual revenue at full scale, but no current revenue or timeline provided.
Risk Factors
- Initiative is early-stage and may not materialize.
- No current revenue or earnings from the partnership.
- Execution risk: requires successful pharmaceutical manufacturing operations.
- Speculative valuation relative to current market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328379 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $1.92 $0.4787 | ▼ −75.07% | ▼ −74.92% | $0.4920 (−74.37%) |
Oct 16, 2026 10d ago | 8-K | $1.92 $0.4787 | ▲ +75.07% | ▲ +74.92% | $0.4920 (+74.37%) |
Aug 27, 2026 8w ago | Press Release | $2.20 $2.11 | ▼ −4.09% | ▼ −4.36% | $0.4920 (−77.64%) |
Aug 24, 2026 9w ago | 8-K | $2.27 $2.15 | ▼ −5.29% | ▼ −5.76% | $0.4920 (−78.33%) |
Aug 20, 2026 9w ago | 8-K | $2.36 $2.20 | ▲ +6.58% | ▲ +7.70% | $0.4920 (+79.11%) |
Jul 16, 2026 14w ago | Press Release | $0.8610 $2.35 | ▲ +172.94% | ▲ +174.61% | $0.4920 (−42.86%) |
Jul 8, 2026 15w ago | Press Release | $0.7531 $0.8610 | ▲ +14.33% | ▲ +14.46% | $0.4920 (−34.67%) |
Jul 2, 2026 16w ago | 8-K | $0.8160 $0.7531 | ▲ +7.71% | ▲ +8.64% | $0.4920 (+39.71%) |
Jun 11, 2026 19w ago | 8-K | $0.8212 $0.7179 | ▼ −12.58% | ▼ −13.25% | $0.4920 (−40.09%) |
Jun 8, 2026 20w ago | EFFECT | $0.7670 $0.7020 | ▲ +8.47% | ▲ +10.59% | $0.4920 (+35.85%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers